Abstract
Background: Human immunodeficiency virus type-1 (HIV-1) infection leads to acquired immunodeficiency syndrome (AIDS), a severe viral infection that has claimed approximately 658,507 lives in the US between the years 2010-2014. Antiretroviral (ARV) therapy has proven to inhibit HIV-1, but unlike other viral illness, not cure the infection. Objective: Among various Food and Drug Administration (FDA)-approved ARVs, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are most effective in limiting HIV-1 infection. This review focuses on NRTIs mechanism of action and metabolism. Methods: A search of PubMed (1982-2016) was performed to capture relevant articles regarding NRTI pharmacology. Results: The current classical NRTIs pharmacology for HIV-1 prevention and treatment are presented. Finally, various novel strategies are proposed to improve the efficacy of NRTIs, which will increase therapeutic efficiency of present-day HIV-1 prevention/treatment regimen. Conclusion: Use of NRTIs will continue to be critical for successful treatment and prevention of HIV-1.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 411-421 |
| Number of pages | 11 |
| Journal | Current HIV Research |
| Volume | 15 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 1 2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Infectious Diseases
- Virology
Cite this
Nucleotide reverse transcriptase inhibitors : A thorough review, present status and future perspective as HIV therapeutics. / Holec, Ashley D.; Mandal, Subhra; Prathipati, Pavan Kumar; Destache, Christopher J.
In: Current HIV Research, Vol. 15, No. 6, 01.12.2017, p. 411-421.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Nucleotide reverse transcriptase inhibitors
T2 - A thorough review, present status and future perspective as HIV therapeutics
AU - Holec, Ashley D.
AU - Mandal, Subhra
AU - Prathipati, Pavan Kumar
AU - Destache, Christopher J.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Background: Human immunodeficiency virus type-1 (HIV-1) infection leads to acquired immunodeficiency syndrome (AIDS), a severe viral infection that has claimed approximately 658,507 lives in the US between the years 2010-2014. Antiretroviral (ARV) therapy has proven to inhibit HIV-1, but unlike other viral illness, not cure the infection. Objective: Among various Food and Drug Administration (FDA)-approved ARVs, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are most effective in limiting HIV-1 infection. This review focuses on NRTIs mechanism of action and metabolism. Methods: A search of PubMed (1982-2016) was performed to capture relevant articles regarding NRTI pharmacology. Results: The current classical NRTIs pharmacology for HIV-1 prevention and treatment are presented. Finally, various novel strategies are proposed to improve the efficacy of NRTIs, which will increase therapeutic efficiency of present-day HIV-1 prevention/treatment regimen. Conclusion: Use of NRTIs will continue to be critical for successful treatment and prevention of HIV-1.
AB - Background: Human immunodeficiency virus type-1 (HIV-1) infection leads to acquired immunodeficiency syndrome (AIDS), a severe viral infection that has claimed approximately 658,507 lives in the US between the years 2010-2014. Antiretroviral (ARV) therapy has proven to inhibit HIV-1, but unlike other viral illness, not cure the infection. Objective: Among various Food and Drug Administration (FDA)-approved ARVs, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are most effective in limiting HIV-1 infection. This review focuses on NRTIs mechanism of action and metabolism. Methods: A search of PubMed (1982-2016) was performed to capture relevant articles regarding NRTI pharmacology. Results: The current classical NRTIs pharmacology for HIV-1 prevention and treatment are presented. Finally, various novel strategies are proposed to improve the efficacy of NRTIs, which will increase therapeutic efficiency of present-day HIV-1 prevention/treatment regimen. Conclusion: Use of NRTIs will continue to be critical for successful treatment and prevention of HIV-1.
UR - http://www.scopus.com/inward/record.url?scp=85042743713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042743713&partnerID=8YFLogxK
U2 - 10.2174/1570162X15666171120110145
DO - 10.2174/1570162X15666171120110145
M3 - Review article
C2 - 29165087
AN - SCOPUS:85042743713
VL - 15
SP - 411
EP - 421
JO - Current HIV Research
JF - Current HIV Research
SN - 1570-162X
IS - 6
ER -